JAZZ Jazz Pharmaceuticals PLC

This article reviews the Q3 earnings of several pharmaceutical companies, highlighting strong overall performance in the sector. Jazz Pharmaceuticals (NASDAQ:JAZZ) specifically reported robust quarterly revenues exceeding expectations and a significant beat on full-year EPS guidance, leading to a substantial stock increase. Other companies like Eli Lilly also showed strong results, though some, like Corcept, fell short of revenue estimates.

Corient Private Wealth LLC significantly reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by 52.8% in Q2 2025, selling 7,189 shares and ending the quarter with 6,437 shares valued at $669,000. Despite this, Jazz Pharmaceuticals holds a "Moderate Buy" consensus rating from analysts with an average price target of $200.47, indicating potential upside. Company insiders have been net sellers, offloading shares worth $22.7 million in the last three months, though they still retain about 4.3% ownership.

Pacer Advisors Inc. reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by 26.5%, selling 194,639 shares and retaining 539,940 shares valued at approximately $71.16 million. Company insiders also sold significant shares, disposing of 129,291 shares totaling $22.7 million in the last quarter. Analysts currently maintain a "Moderate Buy" rating for Jazz Pharmaceuticals, with an average price target of $200.47, and several firms have recently increased their price targets.

Jazz Pharmaceuticals (JAZZ) has seen a significant 35% year-to-date share price rally, outperforming much of the biotech sector. Despite this strong performance, the stock is currently trading at a discount to analyst targets, with a narrative fair value of $213 against a current price of $166.99, suggesting it may still be undervalued, though potential risks like patent expiries and competition exist.

Jazz Pharmaceuticals (JAZZ) has seen a significant share price rally of about 35% year-to-date, trading at $166.99, yet analysts believe it is still undervalued with a narrative fair value of $213. Despite potential risks from patent expiries and competition, investor momentum is building due to pipeline progress and earnings growth. The article suggests exploring the detailed narrative to understand the underlying projections and risks.

Wedge Capital Management L L P NC recently acquired a new stake of 211,185 shares in Jazz Pharmaceuticals PLC ($JAZZ), valued at approximately $27.83 million. Despite this institutional accumulation, company insiders have been net sellers, divesting over $22 million worth of shares in the last 90 days. Wall Street analysts maintain a "Moderate Buy" rating for JAZZ, with an average price target of $200.47.